PIRSのニュース
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/08 20:01:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:08:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec…
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:00:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, …
Pieris Pharmaceuticals''s Return On Capital Employed Insights 2022/08/19 14:18:19 Benzinga
Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ: PIRS ) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter. Pieris Pharmaceuticals collected $10.99 million in revenue during Q1, but reported earnings showed a $5.10 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript 2022/08/06 21:14:03 Seeking Alpha
Pieris Pharmaceuticals, Inc. (NASDAQ:NASDAQ:PIRS) Q2 2022 Results Conference Call August 04, 2022 08:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder -…
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/08 20:01:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer …
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:08:00 Finanz Nachrichten
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec…
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS 2022/08/24 12:00:00 Wallstreet:Online
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, …
Pieris Pharmaceuticals''s Return On Capital Employed Insights 2022/08/19 14:18:19 Benzinga
Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ: PIRS ) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter. Pieris Pharmaceuticals collected $10.99 million in revenue during Q1, but reported earnings showed a $5.10 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript 2022/08/06 21:14:03 Seeking Alpha
Pieris Pharmaceuticals, Inc. (NASDAQ:NASDAQ:PIRS) Q2 2022 Results Conference Call August 04, 2022 08:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder -…
Pieris Pharmaceuticals GAAP EPS of -$0.71 beats by $0.17, revenue of $31.41M beats by $5.97M 2022/03/01 12:18:37 Seeking Alpha
Pieris Pharmaceuticals press release (PIRS): FY GAAP EPS of -$0.71 beats by $0.17.Revenue of $31.41M (+7.1% Y/Y) beats by $5.97M.
Thinking About Buying Stock In Pieris Pharmaceuticals, Baidu Or Cronos Group? 2022/02/28 20:05:47 Benzinga
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for Pieris Pharmaceuticals Inc (NASDAQ: PIRS ), Baidu Inc (NASDAQ: BIDU ) and Cronos Group Inc (NASDAQ: CRON ): Traders and investors will be watching for Pieris’s fourth-quarter earnings report, confirmed for Tuesday’s pre-market session. According to analyst consensus estimates, Pieris is expected to report an EPS loss of 3 cents on revenue of $2.45 million. Pieris reported in November an EPS loss of … Full story available on Benzinga.com
Pieris Pharmaceuticals Q4 2021 Earnings Preview 2022/02/28 19:44:50 Seeking Alpha
Pieris Pharmaceuticals (NASDAQ:PIRS) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$0.25 and the consensus…
Pieris Pharmaceuticals begins dosing in phase 2 gastric cancer study 2022/01/14 13:26:21 Seeking Alpha
Pieris Pharmaceuticals (PIRS) said the first patient was dosed in a phase 2 study of cinrebafusp alfa (PRS-343) to treat HER2-expressing gastric cancer.The trial is evaluating
Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Dont? 2021/12/15 19:41:56 FXNews24
Investors in Pieris Pharmaceuticals, Inc. PIRS need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 18, 2021 $17.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market [] The post Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Dont? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .